{"mainPropery":{"diseaseId":10897,"diseaseName":"Gray zone lymphoma","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/10897/gray-zone-lymphoma","synonyms":[],"synonyms-with-source":[],"identifiers":[]},"diseaseCategories":[{"diseaseTypeId":1,"diseaseTypeName":"Rare Cancers"}],"organizations":[{"resourceID":551,"resourceName":"Lymphoma Research Foundation","abbreviation":"","address1":"Wall Street Plaza","address2":"88 Pine Street, Suite 2400","address3":"","address4":"","address5":"","city":"New York","state":"NY","zip":"10005","country":"United States","phone":"+1-212-349-2910","tty":"","tollFree":"1-800-500-9976","fax":"+1-212-349-2886","email":"helpline@lymphoma.org","url":"https://www.lymphoma.org/","freeText":""},{"resourceID":570,"resourceName":"Leukemia and Lymphoma Society","abbreviation":"","address1":"3 International Drive, Suite 200","address2":"","address3":"","address4":"","address5":"","city":"Rye Brook","state":"NY","zip":"10573","country":"United States","phone":"1-(888) 557-7177 (general)","tty":"","tollFree":"1-(800) 955-4572 (patients and families)","fax":"","email":"https://www.lls.org/content/contact-us","url":"https://www.lls.org/","freeText":""}],"resource descriptions":[{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/pubmed?term=%22gray%20zone%20lymphoma%22%5BAll%20Fields%5D&cmd=DetailsSearch' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Gray zone lymphoma. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2079,"resourceId":2171,"resourceName":"National Cancer Institute","descriptionText":"The&nbsp;<a href='http://www.cancer.gov/types/lymphoma' target='_blank'>National Cancer Institute</a> has information about lymphoma in general.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/DOID:5822' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2155,"resourceId":3362,"resourceName":"Multiple Facebook groups","descriptionText":"Visit the following Facebook groups related to Gray zone lymphoma:<br />\r\n<a href='https://www.facebook.com/groups/719469435450062' target='_blank'>Gray Zone Lymphoma Support Group</a><br />","resourceClassificationName":"Organizations","resourceClassificationSectionName":"Social Networking Websites"}],"overviewQuestion":{"questionId":6201,"questionText":"What is gray zone lymphoma?","answerText":"<strong>Gray zone lymphoma</strong> is a rare type of <a href=\"https://www.nlm.nih.gov/medlineplus/lymphoma.html\" target=\"_blank\">lymphoma</a>, cancer of a part of the immune system called the <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/002247.htm\" target=\"_blank\">lymph system</a>. It is called \"gray zone\" lymphoma because it has features intermediate between classical <a href=\"http://www.cancer.gov/dictionary?CdrID=270800\" target=\"_blank\">Hodgkin lymphoma</a> and <a href=\"https://www.lymphoma.org/aboutlymphoma/nhl/dlbcl/\" target=\"_blank\">diffuse large B-cell lymphoma</a>&nbsp;(DLBCL), but cannot be assigned specifically to either type.[14726][11273] In many cases, the original diagnosis of gray zone lymphoma is later reclassified as a different type of lymphoma, such as nodular sclerosis classical Hodgkin lymphoma (NScHL).[14726] An accurate diagnosis of gray zone lymphoma is challenging, and the clinical characteristics, optimum therapy, and prognosis have not been well-defined.[14726] While some features suggest it should be <a href=\"https://www.cancer.org/cancer/hodgkin-lymphoma/treating.html\" target=\"_blank\">treated like Hodgkin lymphoma</a>, other features suggest it should be <a href=\"https://www.cancer.org/cancer/non-hodgkin-lymphoma/treating/b-cell-lymphoma.html\" target=\"_blank\">treated like DLBCL</a>.[11274]","dateModified":"2018-06-14T00:00:00"},"basicQuestions":[{"questionId":6202,"questionText":"How might&nbsp;gray zone lymphoma be treated?","answerText":"Gray zone lymphoma shares features with two other types of lymphoma, classical <a href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/hodgkin-lymphoma\" target=\"_blank\">Hodgkin lymphoma</a> (cHL)&nbsp;and <a href=\"https://www.lymphoma.org/aboutlymphoma/nhl/dlbcl/\" target=\"_blank\">diffuse large B-cell lymphoma</a> (DLBCL). Because these lymphomas are treated differently, the optimal therapy for gray zone lymphoma is unclear. Because there are no consensus guidelines for the best treatment of gray zone lymphoma, treatment is currently determined based on each individual's diagnosis.[5233] In general, treatment usually involves&nbsp;<a href=\"http://www.cancer.gov/dictionary?CdrID=45214\" target=\"_blank\">chemotherapy</a>&nbsp;(with the specific drugs depending upon each person's treatment plan), which may be followed by&nbsp;<a href=\"http://www.cancer.gov/dictionary?CdrID=44971\" target=\"_blank\">radiation therapy</a>&nbsp;in some cases.[5233] Some research has suggested that treatment with DLBCL-based regimens is the most effective for some people (such as the drug combination <a href=\"https://www.cancer.gov/about-cancer/treatment/drugs/R-CHOP\" target=\"_blank\">R-CHOP</a> or dose-adjusted <a href=\"https://www.cancer.gov/about-cancer/treatment/drugs/R-EPOCH\" target=\"_blank\">EPOCH-R</a>), but additional research is needed.[14726] Individual case reports have reported success with different <a href=\"https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/immune-checkpoint-inhibitors.html\" target=\"_blank\">PD-1 inhibitors</a>&nbsp;(such as <a href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/pembrolizumab\" target=\"_blank\">pembrolizumab</a> and <a href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/nivolumab\" target=\"_blank\">nivolumab</a>), but larger studies are needed to determine if this might be an effective new strategy for treating gray zone lymphoma.[14727]","dateModified":"2018-06-14T00:00:00","resourceClassificationName":"Treatment","references":[{"referenceId":5233,"authors":"Traverse-Glehen A, Pittaluga S, Gaulard P, Sorbara L, Alonso MA, Raffeld M, Jaffe ES","articleTitle":"Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma","bookWebsiteJournalTitle":"American Journal of Surgical Pathology","date":"2005","volume":"29","pages":"1411-1421","url":"http://www.ncbi.nlm.nih.gov/pubmed/16224207","dateAccessed":"2012-05-12T00:00:00"},{"referenceId":14726,"authors":"Pilichowska M, Pittaluga S, Ferry JA, et al","articleTitle":"Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL","bookWebsiteJournalTitle":"Blood Adv","date":"December 11, 2017","volume":"1(26)","pages":"2600-2609","url":"http://www.bloodadvances.org/content/1/26/2600?sso-checked=true","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":14727,"authors":"Melani C, Major A, Schowinsky J, et al","articleTitle":"PD-1 Blockade in Mediastinal Gray-Zone Lymphoma","bookWebsiteJournalTitle":"N Engl J Med","date":"July 6, 2017","volume":"377(1)","pages":"89-91","url":"https://www.nejm.org/doi/full/10.1056/NEJMc1704767","authors2":"","placeOfPublication":"","publisher":""}]}],"references":[],"relatedDiseases":[{"relatedDiseaseId":11955,"relatedDiseaseName":"Lymphoma","relation":"Parent","isRare":false,"hasGardPage":false}],"gardCases":[{"caseId":35190,"abbreviatedInquiry":"My husband has been diagnosed with gray zone lymphoma.&nbsp; What are the&nbsp;treatment options for this condition?","caseQuestions":[{"questionId":6202,"questionText":"How might&nbsp;gray zone lymphoma be treated?","answerText":"Gray zone lymphoma shares features with two other types of lymphoma, classical <a href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/hodgkin-lymphoma\" target=\"_blank\">Hodgkin lymphoma</a> (cHL)&nbsp;and <a href=\"https://www.lymphoma.org/aboutlymphoma/nhl/dlbcl/\" target=\"_blank\">diffuse large B-cell lymphoma</a> (DLBCL). Because these lymphomas are treated differently, the optimal therapy for gray zone lymphoma is unclear. Because there are no consensus guidelines for the best treatment of gray zone lymphoma, treatment is currently determined based on each individual's diagnosis.[5233] In general, treatment usually involves&nbsp;<a href=\"http://www.cancer.gov/dictionary?CdrID=45214\" target=\"_blank\">chemotherapy</a>&nbsp;(with the specific drugs depending upon each person's treatment plan), which may be followed by&nbsp;<a href=\"http://www.cancer.gov/dictionary?CdrID=44971\" target=\"_blank\">radiation therapy</a>&nbsp;in some cases.[5233] Some research has suggested that treatment with DLBCL-based regimens is the most effective for some people (such as the drug combination <a href=\"https://www.cancer.gov/about-cancer/treatment/drugs/R-CHOP\" target=\"_blank\">R-CHOP</a> or dose-adjusted <a href=\"https://www.cancer.gov/about-cancer/treatment/drugs/R-EPOCH\" target=\"_blank\">EPOCH-R</a>), but additional research is needed.[14726] Individual case reports have reported success with different <a href=\"https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/immune-checkpoint-inhibitors.html\" target=\"_blank\">PD-1 inhibitors</a>&nbsp;(such as <a href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/pembrolizumab\" target=\"_blank\">pembrolizumab</a> and <a href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/nivolumab\" target=\"_blank\">nivolumab</a>), but larger studies are needed to determine if this might be an effective new strategy for treating gray zone lymphoma.[14727]","dateModified":"2018-06-14T00:00:00","resourceClassificationName":"Treatment","references":[{"referenceId":5233,"authors":"Traverse-Glehen A, Pittaluga S, Gaulard P, Sorbara L, Alonso MA, Raffeld M, Jaffe ES","articleTitle":"Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma","bookWebsiteJournalTitle":"American Journal of Surgical Pathology","date":"2005","volume":"29","pages":"1411-1421","url":"http://www.ncbi.nlm.nih.gov/pubmed/16224207","dateAccessed":"2012-05-12T00:00:00"},{"referenceId":14726,"authors":"Pilichowska M, Pittaluga S, Ferry JA, et al","articleTitle":"Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL","bookWebsiteJournalTitle":"Blood Adv","date":"December 11, 2017","volume":"1(26)","pages":"2600-2609","url":"http://www.bloodadvances.org/content/1/26/2600?sso-checked=true","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":14727,"authors":"Melani C, Major A, Schowinsky J, et al","articleTitle":"PD-1 Blockade in Mediastinal Gray-Zone Lymphoma","bookWebsiteJournalTitle":"N Engl J Med","date":"July 6, 2017","volume":"377(1)","pages":"89-91","url":"https://www.nejm.org/doi/full/10.1056/NEJMc1704767","authors2":"","placeOfPublication":"","publisher":""}]}]}],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[],"medicalProducts":[],"EncodedName":"Gray_zone_lymphoma"}